HCPCS Level II Code Changes in Effect July 1

C1748Endoscope, single-use (i.e. disposable), upper gi, imaging/illumination device (insertable)C1849Skin substitute, synthetic, resorbable, per square centimeterC9059Injection, meloxicam, 1 mgC9061Injection, teprotumumab-trbw, 10 mgC9063Injection, eptinezumab-jjmr, 1 mgC9122Mometasone furoate sinus implant, 10 micrograms (sinuva)C9759Transcatheter intraoperative blood vessel microinfusion(s) (e.g., intraluminal, vascular wall and/or perivascular) therapy, any vessel, including radiological supervision and interpretation, when performedC9760Non-randomized, non-blinded procedure for nyha class ii, iii, iv heart failure; transcatheter implantation of interatrial shunt or placebo control, including right and left heart catheterization, transeptal puncture, trans-esophageal echocardiography (tee)/intracardiac echocardiography (ice), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (ide) studyC9762Cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with strain imagingC9763Cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with stress imagingC9764Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy, includes angioplasty within the same vessel(s), when performedC9765Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessel(s), when performedC9766Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel(s), when performedC9767Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same vessel(s), when performedC9803Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), any specimen sourceG2025Payment for a telehealth distant site service furnished by a rural health clinic (RHC) or federally qualified health center (FQHC) onlyG2170Percutaneous arteriovenous fistula creation (AVF), direct, any site, by tissue approximation using thermal resistance energy, and secondary procedures to redirect blood flow (e.g., transluminal balloon angioplasty, coil embolization) when performed, and includes all imaging and radiologic guidance, supervision and interpretation, when performedG2171Percutaneous arteriovenous fistula creation (AVF), direct, any site, using magnetic-guided arterial and venous catheters and radiofrequency energy, including flow-directing procedures (e.g., vascular coil embolization with radiologic supervision and interpretation, wen performed) and fistulogram(s), angiography, enography, and/or ultrasound, with radiologic supervision and interpretation, when performedJ0223Injection, givosiran, 0.5 mgJ0591Injection, deoxycholic acid, 1 mgJ0691Injection, lefamulin, 1 mgJ0742Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mgJ0791Injection, crizanlizumab-tmca, 0.5 mgJ0896Injection, luspatercept-aamt, 0.25 mgJ1201Injection, cetirizine hydrochloride, 0.5 mgJ1429Injection, golodirsen, 10 mgJ1558Injection, immune globulin (Xembify), 100 mgJ3399Injection, Onasemnogene abeparvovec-xioi, per treatment, up to 5×1015 vector genomesJ7169Injection, coagulation factor xa (recombinant), inactivated-zhzo (andexxa), 10 mgJ7204Injection, factor viii, antihemophilic factor (recombinant), (esperoct), glycopegylated-exei, per iuJ7333Hyaluronan or derivative, visco-3, for intra-articular injection, per doseJ9177Injection, enfortumab vedotin-ejfv, 0.25 mgJ9198Injection, gemcitabine hydrochloride, (infugem), 100 mgJ9246Injection, melphalan (evomela), 1 mgJ9358Injection, fam-trastuzumab deruxtecan-nxki, 1 mgQ4227Amniocore, per square centimeterQ4228Bionextpatch, per square centimeterQ4229Cogenex amniotic membrane, per square centimeterQ4230Cogenex flowable amnion, per 0.5 ccQ4231Corplex P, per ccQ4232Corplex, per square centimeterQ4233Surfactor or nudyn, per 0.5 ccQ4234Xcellerate, per square centimeterQ4235Amniorepair or altiply, per square centimeterQ4236Carepatch, per square centimeterQ4237Cryo-cord, per square centimeterQ4238Derm-maxx, per square centimeterQ4239Amnio-maxx or amnio-maxx lite, per square centimeterQ4240Corecyte, for topical use only, per 0.5 ccQ4241Polycyte, for topical use only, per 0.5 ccQ4242Amniocyte plus, per 0.5 ccQ4244Procenta, per 200 mgQ4245Amniotext, per ccQ4246Coretext or protext, per ccQ4247Amniotext patch, per square centimeterQ4248Dermacyte amniotic membrane allograft, per square centimeterQ5119*Injection, Rituximab-pvvr, biosimilar, (Ruxience), 10 mgQ5120*Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mgQ5121Injection, infliximab-axxq, biosimilar, (avsola), 10 mgU0003Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-RU00042019-nCoV coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R
Translate »